Pharmaceutical composition for treatment of dry eye syndrome
The invention provides novel pharmaceutical compositions for the treatment of keratoconjunctivitis sicca comprising liquid vehicles which include one or more semifluorinated alkanes. The compositions incorporate an active ingredient selected from the group of macrolide immunosuppressants. They can be administered topically into the eye. The invention further provides kits comprising such compositions.
1. A pharmaceutical composition comprising:
(a) a therapeutically effective amount of an active ingredient selected from the group of macrolide immunosuppressants useful in the prevention or therapy of keratoconjunctivitis sicca or a symptom associated therewith, and
(b) liquid vehicle comprising a semifluorinated alkane, wherein the pharmaceutical composition is formulated as a clear solution.
2. The composition of claim 1 , wherein the active ingredient exhibits a water solubility of less than about 1 mg per ml, as measured at room temperature and neutral pH.
3. The composition of claim 2 , wherein the active ingredient is ciclosporin A.
4. The composition of claim 3 , wherein the concentration of ciclosporin A is from about 0.01 wt.-% to about 0.5 wt.-%.
5. The composition of claim 1 , wherein the semifluorinated alkane is a compound of formula
RFRH
or of formula
RFRHRF
wherein RF is a perfluorinated hydrocarbon segment with 20 or less carbon atoms, and
wherein RH is a non-fluorinated hydrocarbon segment with 3 to 20 carbon atoms.
6. The composition of claim 5 , wherein the semifluorinated alkane is a compound of formula
RFRH
wherein RF is a linear perfluorinated hydrocarbon segment with 3 to 10 carbon atoms, and
wherein RH is a linear alkyl group with 3 to 10 carbon atoms.
7. The composition of claim 6 , wherein the semifluorinated alkane is selected from F4H5, F4H6, F6H6 and F6H8.
8. The composition of claim 1 , being effectively free of water.
9. The composition of claim 1 , further comprising an organic cosolvent.
10. A pharmaceutical composition comprising:
(a) a therapeutically effective amount of an active ingredient selected from the group of macrolide immunosuppressants useful in the prevention or therapy of keratoconjunctivitis sicca or a symptom associated therewith;
(b) a liquid vehicle comprising a semifluorinated alkane; and
(C) ethanol.
11. The composition of claim 10 , comprising ethanol at a concentration of about 1 wt.-% or less.
12. A pharmaceutical kit comprising the composition of claim 1 and a container holding the composition, wherein the container has a dispensing means adapted for topically administering the composition to the eye of a patient.
13. The composition of claim 6 , wherein the semifluorinated alkane is F4H5.